Story perspectives

Lilly Beats Forecasts, Raises Outlook, Gains 60% GLP-1 Share

5/1/2026

45 3

Summary

Story summary

Eli Lilly & Co. posted earnings that beat forecasts and lifted its full-year profit outlook to $35.50-$37 per share.
Revenue rose 56% to $19.80 billion, with U.S. sales of $12.1 billion, while Mounjaro and Zepbound generated $8.66 billion and $4.16 billion respectively, giving Lilly a 60.1% share of the U.S. GLP-1 market.
Net income was $7.40 billion ($8.26 per share) with adjusted EPS $8.55, while the stock rose more than 9% in late-morning trading Thursday.

1 of 1

Story summary

Eli Lilly & Co. posted earnings that beat forecasts and lifted its full-year profit outlook to $35.50-$37 per share.
Revenue rose 56% to $19.80 billion, with U.S. sales of $12.1 billion, while Mounjaro and Zepbound generated $8.66 billion and $4.16 billion respectively, giving Lilly a 60.1% share of the U.S. GLP-1 market.
Net income was $7.40 billion ($8.26 per share) with adjusted EPS $8.55, while the stock rose more than 9% in late-morning trading Thursday.